BMC Nephrology (Aug 2012)

Effect of add-on direct renin inhibitor aliskiren in patients with non-diabetes related chronic kidney disease

  • Li Szu-yuan,
  • Chen Yung-Tai,
  • Yang Wu-Chang,
  • Tarng Der-Cherng,
  • Lin Chih-Ching,
  • Yang Chih-Yu,
  • Liu Wen-Sheng

DOI
https://doi.org/10.1186/1471-2369-13-89
Journal volume & issue
Vol. 13, no. 1
p. 89

Abstract

Read online

Abstract Background The renin-angiotensin-aldosterone system (RAAS) plays an important role in the progression of chronic kidney disease (CKD). Although dual RAAS inhibition results in worse renal outcomes than monotherapy in high risk type 2 diabetes patients, the effect of dual RAAS inhibition in patients with non-DM CKD is unclear. The aim of this study was to evaluate the potential renoprotective effect of add-on direct renin inhibitor in non-DM CKD patients. Methods We retrospectively enrolled 189 non-DM CKD patients who had been taking angiotensin II receptor blockers (ARBs) for more than six months. Patients were divided into an add-on aliskiren group and an ARB monotherapy group. The primary outcomes were a decline in glomerular filtration rate (GFR) and a reduction in urinary protein-to-creatinine ratio at six months. Results The baseline characteristics of the two groups were similar. Aliskiren 150 mg daily reduced the urinary protein-to-creatinine ratio by 26% (95% confidence interval, 15 to 37%; p Conclusion Add-on direct renin inhibitor aliskiren (150 mg daily) safely reduced proteinuria and attenuated the decline in GFR in the non-DM CKD patients who were receiving ARBs.

Keywords